AbbVie Stock Poised for New All-Time Highs in 2024

AbbVie had a better-than-expected quarter and guided higher; the post-release price drop is a dip you can buy.

The two analysts' revisions tracked by Marketbeat include lowered price targets, but they are still at the high end of the expected range and project upside for investors. The consensus estimate forecasts a slim 6% increase for the stock, but the high-end adds another 7% to that target and opens the door for much larger gains because it would be a new all-time high for this healthcare stock.

The guidance is the most favorable aspect of the report and includes an increase in the expected earnings. The company raised its full-year adjusted EPS guidance to a range with the low end above consensus. Because the company is building momentum in the non-Humira portfolio and Humira sales are still solid, guidance may increase later in the year. The pipeline plays into that outlook with several positive developments over the quarter, including the acquisition of ImmunoGen .

Source: News Formal (newsformal.com)

United States Latest News, United States Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

Meta Stock: 3 Reasons This Stumble Is a Golden Buying OpportunityStocks Analysis by MarketBeat.com (Sam Quirke) covering: Truist Financial Corp, Meta Platforms Inc. Read MarketBeat.com (Sam Quirke)'s latest article on Investing.com
Source: Investingcom - 🏆 450. / 53 Read more »

Healthy Returns: Sales of Humira are plunging, but AbbVie has two promising successorsAbbVie has two successors that could offset the losses from its blockbuster drug Humira. Meanwhile, UnitedHealth Group’s CEO will testify on Capitol Hill.
Source: NBCLA - 🏆 319. / 59 Read more »

Healthy Returns: Sales of Humira are plunging, but AbbVie has two promising successorsAbbVie has two successors that could offset the losses from its blockbuster drug Humira. Meanwhile, UnitedHealth Group’s CEO will testify on Capitol Hill.
Source: NBCPhiladelphia - 🏆 569. / 51 Read more »

Jim Cramer's quick thoughts on 5 stocks: Chevron, Snap, Intel, AbbVie and ColgateJim Cramer offers his take on companies outside the CNBC Investing Club’s portfolio.
Source: CNBC - 🏆 12. / 72 Read more »

Drugmaker AbbVie expects Humira volume erosion to worsenDrugmaker AbbVie expects Humira volume erosion to worsen
Source: Investingcom - 🏆 450. / 53 Read more »

Molly Ringwald: My John Hughes Films Are ‘Really, Really, Very White,’ Remakes Would Need More DiversitySource of breaking news and analysis, insightful commentary and original reporting, curated and written specifically for the new generation of independent and conservative thinkers.
Source: BreitbartNews - 🏆 610. / 51 Read more »